From GlobeNewswire: 2024-04-10 07:00:00

Nurix Therapeutics, a biopharmaceutical company, extended collaborations with Gilead Sciences and Sanofi to develop new drugs for cancer and inflammatory diseases. They presented case studies on NX-5948 showing positive responses in patients with CNS lymphoma and CLL. Nurix is part of a team selected for a Cancer Grand Challenges award for pediatric cancer research(Nasdaq: NRIX). They reported financial results for the first quarter, with revenue of $16.6 million. Nurix’s lead drug candidate, NX-5948, is in a Phase 1 trial for B-cell malignancies. They plan to present additional clinical data in mid-2024. Another drug candidate, NX-2127, is for B-cell malignancies and will resume enrollment following FDA approval lift. Nurix also has other drugs in the pipeline for immuno-oncology and inflammatory diseases.



Read more at GlobeNewswire:: Nurix Therapeutics Reports First Quarter Fiscal 2024